Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 8/2020

01.08.2020 | Rhinitis, Conjunctivitis, and Sinusitis (J Corren and J Oppenheimer, Section Editors)

Utility of Environmental Exposure Unit Challenge Protocols for the Study of Allergic Rhinitis Therapies

verfasst von: Lubnaa Hossenbaccus, Lisa M. Steacy, Terry Walker, Anne K. Ellis

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This paper explores how the Environmental Exposure Unit (EEU) experimental model can be used to further our understanding of pharmacotherapies and immunotherapies for the treatment of allergic rhinitis (AR).

Recent Findings

EEUs are used increasingly for the study of combination therapies, immunotherapies, and novel AR treatments. A combined antihistamine/corticosteroid nasal spray formulation was seen to have a faster onset of action relative to the therapies individually in the Environmental Exposure Chamber. House dust mite sublingual immunotherapy tablets are both safe and efficacious as evaluated by the Vienna Challenge Chamber. The Kingston EEU found that a novel peptide-based immunotherapy approach to be effective in reducing grass pollen-induced AR. Lastly, nasal filters were determined to reduce seasonal AR symptoms, given out-of-season in the Denmark Environmental Exposure Unit.

Summary

EEUs are controlled, replicable models that provide valuable insight into the efficacy, onset and duration of action, and dose-related impacts of AR therapeutics, with direct clinical relevance.
Literatur
1.
2.
3.
Meltzer EO, Gross GN, Katial R, Storms WW. Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract. 2012;61.
4.
• Passali D, Cingi C, Staffa P, Passali F, Muluk NB, Bellussi ML. The international study of the allergic rhinitis survey: outcomes from 4 geographical regions. Asia Pac Allergy. 2018;8. https://​doi.​org/​10.​5415/​apallergy.​2018.​8.​e7. This is a cross-sectional, a questionnaire survey concerning AR was completed across different countries in Asia, Europe, the Americas, and Africa. The prevalence of AR was reported to be 15%-25%.
5.
Small P, Keith PK, Kim H. Allergic rhinitis. Allergy, Asthma Clin Immunol. 2018;14:51.CrossRef
6.
Day JH, Ellis AK, Rafeiro E, Ratz JD, Briscoe MP. Experimental models for the evaluation of treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2006;96:263–78.PubMedCrossRef
7.
Ellis AK, North ML, Walker T, Steacy LM. Environmental exposure unit: a sensitive, specific, and reproducible methodology for allergen challenge. Ann Allergy Asthma Immunol. 2013;111:323–8.PubMedCrossRef
8.
Day JH, Horak F, Briscoe MP, Canonica GW, Fineman SM, Krug N, et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev. 2006;6:31–59.CrossRef
9.
•• Ellis AK, Jacobs RL, Tenn MW, et al (2019) Clinical standardization of two controlled allergen challenge facilities: the Environmental Exposure Unit and the Biogenics Research Chamber. Ann Allergy, Asthma Immunol 122:639-646.e2. This article demonstrates equivalent results between 2 CACFs, one located in Kingston, Canada and the other in San Antonio, USA in a double-blind,placebo-controlled, crossover intervention trial.
10.
Horak, F. and SJ (1987) The Vienna challenge chamber (VCC)—a new method for allergen exposition tests. Wiener Klin Wochenschrift 99:509–510.
11.
Pross HF, Day JH, Clark RH, Lees REM. Immunologic studies of subjects with asthma exposed to formaldehyde and urea-formaldehyde foam insulation (UFFI) off products. J Allergy Clin Immunol. 1987;79:797–810.PubMedCrossRef
12.
13.
Ramirez DA, Jacobs RL, Andrews CP. Juniperus asheii (mountain cedar) pollen utilized as an antigen in the biogenics chamber: comparison of natural and controlled exposures. J Allergy Clin Immunol. 2011;127:AB19–9.
14.
Jacobs RL, Ramirez DA, Andrews CP. Validation of the biogenics research chamber for Juniperus ashei (mountain cedar) pollen. Ann Allergy Asthma Immunol. 2011;107:133–8.PubMedCrossRef
15.
Rønborg SM, Mosbech H, Johnsen CR, Poulsen LK. Exposure chamber for allergen challenge the development and validation of a new concept. Allergy. 1996;51:82–8.PubMedCrossRef
16.
Kelly S, Yang J, Perrins R, Karsh J, Yang WH. Technical evaluation of an allergen Challenge Theatre™. Allergy, Asthma Clin Immunol. 2014;10:A22.CrossRef
17.
Krug N, Loedding H, Hohlfeld JM, Larbig M, Buckendahl A, Badorrek P, et al. Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis. Clin Exp Allergy. 2003;33:1667–74.PubMedCrossRef
18.
Hamasaki S, Okamoto Y, Yonekura S, Okuma Y, Sakurai T, Iinuma T, et al. Characteristics of the Chiba environmental challenge chamber. Allergol Int. 2014;63:41–50.PubMedCrossRef
19.
Ito K, Terada T, Yuki A, Ichihara T, Hyo S, Kawata R, et al. Preliminary study of a challenge test to the patients with Japanese cedar pollinosis using an environmental exposure unit. Auris Nasus Larynx. 2010;37:694–9.PubMedCrossRef
20.
Baroody FM, Naclerio RM. Antiallergic effects of H1-receptor antagonists. Allergy Eur. J. Allergy Clin. Immunol. Suppl. 2000:17–27.
21.
•• Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI position statement: newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy, Asthma Clin Immunol. 2019;15:61. A CSACI position statement presenting that newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria.
22.
• Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K. Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. Int J Mol Sci. 2019;20. https://​doi.​org/​10.​3390/​ijms20010213. This article evaluates the non-sedative effects of antihistamines in AR treatment, recommending non-brain-penetrating antihistamines as first-line therapy of mild AR.
23.
Day JH, Briscoe MP, Clark RH, Ellis AK, Gervais P. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79:163–72.PubMedCrossRef
24.
Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998;101:638–45.PubMedCrossRef
25.
Day JH, Briscoe M, Rafeiro E, Chapman D, Kramer B. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol. 2001;87:474–81.PubMedCrossRef
26.
• Snidvongs K, Seresirikachorn K, Khattiyawittayakun L, Chitsuthipakorn W. Sedative effects of levocetirizine: a systematic review and meta-analysis of randomized controlled studies. Drugs. 2017;77:175–86. This study investigates the sedative effects of levocetirizine compared to placebo, demonstrating modest effects, though not significantly different fromother second-generation antihistamines.
27.
Tillement J-P, Testa B, Brée F. Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem Pharmacol. 2003;66:1123–6.PubMedCrossRef
28.
Stübner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opin. 2004;20:891–902.PubMedCrossRef
29.
Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol. 2001;107:751–62.PubMedCrossRef
30.
Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of-seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract. 2004;58:109–18.PubMedCrossRef
31.
Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol. 2005;60:24–31.PubMedPubMedCentralCrossRef
32.
Terrien MH, Rahm F, Fellrath JM, Spertini F. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. J Allergy Clin Immunol. 1999;103:1025–30.PubMedCrossRef
33.
Day JH, Briscoe MP, Rafeiro E, Hewlett D, Chapman D, Kramer B. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2004;25:59–68.PubMed
34.
Day JH, Briscoe MP, Rafeiro E, Ratz JD, Ellis AK, Frankish CW, et al. Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unit. Allergy Asthma Proc. 2005;26:275–82.PubMed
35.
Day JH, Briscoe MP, Welsh A, Smith JN, Clark A, Ellis AK, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol. 1997;79:533–40.PubMedCrossRef
36.
Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010;59:391–8.PubMedCrossRef
37.
Ellis AK, Zhu Y, Steacy LM, Walker T, Day JH. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. Allergy, Asthma Clin Immunol. 2013;9. https://​doi.​org/​10.​1186/​1710-1492-9-16.
38.
•• Tenn MW, Steacy LM, Ng CC, Ellis AK. Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score. Allergy, Asthma Clin Immunol. 2018;14:5. In this article, the onset of action of loratadine tablets was determined to be 75 mins was investigtaed in the Environmental Exposure Unit for seasonal AR.
39.
Horak F, Zieglmayer UP, Zieglmayer R, Kavina A, Marschall K, Munzel U, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin. 2006;22:151–7.CrossRefPubMed
40.
Patel P, Roland PS, Marple BF, Benninger PJ, Margalias H, Brubaker M, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg. 2007;137:918–24.PubMedCrossRef
41.
Yonekura S, Okamoto Y, Yamamoto H, Sakurai T, Iinuma T, Sakurai D, et al. Randomized double-blind study of prophylactic treatment with an antihistamine for seasonal allergic rhinitis. Int Arch Allergy Immunol. 2013;162:71–8.PubMedCrossRef
42.
Stuebner P, Horak F, Zieglmayer R, Arnáiz E, Leuratti C, Pérez I, et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol. 2006;96:37–44.PubMedCrossRef
43.
Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006;36:689–703.PubMedPubMedCentralCrossRef
44.
Day JH, Briscoe MP, Ratz JD. Efficacy of levocetirizine compared with montelukast in subjects with ragweed-induced seasonal allergic rhinitis in the environmental exposure unit. Allergy Asthma Proc. 2008;29:304–12.PubMedCrossRef
45.
Patel P, Patel D. Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients. Ann Allergy Asthma Immunol. 2008;101:287–94.PubMedCrossRef
46.
Trangsrud AJ, Whitaker AL, Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy. 2002;22:1458–67.PubMedCrossRef
47.
•• Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140:950–8. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines present recommendations to support patients, their caregivers, and health care providers in choosing the optimal AR treatment, which might improve patients' quality of life and school and work productivity.
48.
Mabry RL. Corticosteroids in the management of upper respiratory allergy: the emerging role of steroid nasal sprays. Otolaryngol Head Neck Surg. 1992;107:855–9 discussion 859-60.PubMedCrossRef
49.
Day JH, Briscoe MP, Rafeiro E, Ellis AK, Pettersson E, Åkerlund A. Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. J Allergy Clin Immunol. 2000;105:489–94.PubMedCrossRef
50.
Day JH, Buckeridge DL, Clark RH, Briscoe MP, Phillips R. A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1996;97:1050–7.PubMedCrossRef
51.
52.
53.
Badorrek P, Hohlfeld JM, Krug N, Joshi A, Raut A. Efficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2015;115:325–329.e1.PubMedCrossRef
54.
Ellis AK, Steacy LM, Joshi A, Bhowmik S, Raut A. Efficacy of the novel nasal steroid S0597 tested in an environmental exposure unit. Ann Allergy Asthma Immunol. 2016;117:310–7.PubMedCrossRef
55.
Patel P, D’Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol. 2007;21:499–503.PubMedCrossRef
56.
Patel D, Garadi R, Brubaker M, Conroy PJ, Kaji Y, Crenshaw K, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: Olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc. 2007;28:592–9.CrossRefPubMed
57.
Van Cauwenberge P, Van Hcecke H, Bousquet J (2005) Allergic rhinitis and its impact on asthma. In: Pediatr. Nasal Sinus Disord. CRC Press, pp 402–422.
58.
Yamamoto H, Yonekura S, Sakurai D, Katada K, Inamine A, Hanazawa T, et al. Comparison of nasal steroid with antihistamine in prophylactic treatment against pollinosis using an environmental challenge chamber. Allergy Asthma Proc. 2012;33:397–403.PubMedCrossRef
59.
Zieglmayer P, Zieglmayer R, Bareille P, Rousell V, Salmon E, Horak F. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin. 2008;24:1833–40.PubMedCrossRef
60.
Salapatek AM, Patel P, Gopalan G, Varghese ST. Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am J Rhinol Allergy. 2010;24:433–8.PubMedCrossRef
61.
Day JH, Briscoe MP, Ratz JD, Ellis AK, Yao R, Danzig M. Onset of action of loratadine/montelukast in seasonal allergic rhinitis subjects exposed to ragweed pollen in the Environmental Exposure Unit. Allergy Asthma Proc. 2009;30:270–6.PubMedCrossRef
62.
Horak F, Zieglmayer P, Zieglmayer R, Lemell P. Onset of action of loratadine/montelukast in seasonal allergic rhinitis patients exposed to grass pollen. Arzneimittel-Forschung/Drug Res. 2010;60:249–55.
63.
Johnson DA, Hricik JG. The pharmacology of α-adrenergic decongestants. Pharmacother J Hum Pharmacol Drug Ther. 1993;13:110S–5S.
64.
Badorrek P, Dick M, Schauerte A, Hecker H, Murdoch R, Luettig B, et al. A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis. Int J Clin Pharmacol Ther. 2009;47:71–7.PubMedCrossRef
65.
Zieglmayer UP, Horak F, Toth J, Marks B, Berger UE, Burtin B. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus budesonide nasal spray in the management of nasal congestion in allergic rhinitis. Treat Respir Med. 2005;4:283–7.PubMedCrossRef
66.
Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Yao R, Staudinger H, et al. A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol. 2009;102:116–20.PubMedCrossRef
67.
Day JH, Briscoe MP, Ratz JD, Danzig M, Yao R. Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Ann Allergy Asthma Immunol. 2009;102:328–38.PubMedCrossRef
68.
Berkowitz RB, Woodworth GG, Lutz C, Weiler K, Weiler J, Moss M, et al. Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. Ann Allergy Asthma Immunol. 2002;89:38–45.PubMedCrossRef
69.
Chervinsky P, Nayak A, Rooklin A, Danzig M. Efficacy and safety of desloratadine/pseudoephedrine tablet, 2.5/120 mg two times a day, versus individual components in the treatment of patients with seasonal allergic rhinitis. Allergy asthma Proc. 2005;26:391–6.PubMed
70.
Daley-Yates P, Ambery C, Sweeney L, Watson J, Oliver A, McQuade B. The efficacy and tolerability of two novel H 1/H 3 receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol. 2012;158:84–98.PubMedCrossRef
71.
•• North ML, Walker T, Steacy LM, Hobsbawn BG, Allan RJ, Hackman F, et al. Double blind randomized crossover trial of PF-03654764+fexofenadine in the environmental exposure unit (EEU). Allergy, Asthma Clin Immunol. 2014;10:A68. This double blind randomized crossover trial of PF-03654764+fexofenadine in the Environmental Exposure Unit found improved TNSS compared toplacebo, with insignificant side effects.
72.
•• Roca-Ferrer J, Pujols L, Pérez-González M, Alobid I, Callejas B, Vicens-Artés S, et al. Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers. Allergy, Asthma Clin Immunol. 2018;14:86. This study found superior clinical efficacy with MP-AzeFlu than azelastine or fluticasone propionate alone in reducing inflammatory markers.
73.
Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract. 2018;6:1726–1732.e6.PubMedCrossRef
74.
Salapatek AM, Lee J, Patel D, D’Angelo P, Liu J, Zimmerer RO, et al. Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis. Allergy Asthma Proc. 2011;32:221–9.PubMedCrossRef
75.
Moote W, Kim H. Allergen-specific immunotherapy. Allergy, Asthma Clin Immunol. 2011;7:S5.CrossRef
76.
• Donovan JP, Buckeridge DL, Briscoe MP, Clark RH, Day JH. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol. 1996;77:74–80. Ragweed antigen immunotherapy was evaluated in a controlled ragweed allergen exposure showed significantly reduced symptoms of ragweed-allergic rhinitis with no significant effect on ocular symptoms.
77.
Roux M, Viatte A, Zeldin RK. Safety of a sublingual tablet of house dust mite allergen extracts in an environmental exposure chamber study. J Allergy Clin Immunol. 2015;135:AB266.CrossRef
78.
Roux M, Yang WH, Viatte A, Cadic VZR. Efficacy of house dust mite sublingual tablets in an environmental exposure chamber study of patients with house dust mite-associated allergic rhinitis | Cochrane Library. Allergy Eur J allergy Clin Immunol. 2013;68:5–6.
79.
Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015;135:1494–1501.e6.PubMedCrossRef
80.
Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009;124:471–7 477.e1.PubMedCrossRef
81.
Ellis AK, Tenn MW, Steacy LM, Adams DE, Day AG, Walker TJ, et al. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen–induced allergic rhinoconjunctivitis in an environmental exposure unit. Ann Allergy, Asthma Immunol. 2018;120:495–503.e2.CrossRef
82.
Ellis AK, Frankish CW, O’Hehir RE, Armstrong K, Steacy L, Larché M, et al. Treatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2017;140:486–96.PubMedCrossRef
83.
•• Patel P, Holdich T, Fischer Von Weikersthal-Drachenberg KJ, Huber B (2014) Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol 133:121–9.e1–2. This study demonstrated that an ultrashort course of ragweed immunotherapy is efficacious in reducing allergy symptoms in patients with seasonal AR and that it is well tolerated.
84.
Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131:103–9.e1–7.PubMedCrossRef
85.
Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy Eur J Allergy Clin Immunol. 2012;67:1572–9.
86.
Krug N, Gupta A, Badorrek P, Koenen R, Mueller M, Pivovarova A, et al. Efficacy of the oral chemoattractant receptor homologous molecule on T H2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2014;133:414–9.PubMedCrossRef
87.
Kenney P, Hilberg O, Pedersen H, Nielsen OB, Sigsgaard T. Rhinix™ nasal filters for the treatment of allergic rhinitis: a randomized, double-blinded placebo-controlled crossover clinical trial. J Allergy Clin Immunol. 2014;133:AB186.CrossRef
Metadaten
Titel
Utility of Environmental Exposure Unit Challenge Protocols for the Study of Allergic Rhinitis Therapies
verfasst von
Lubnaa Hossenbaccus
Lisa M. Steacy
Terry Walker
Anne K. Ellis
Publikationsdatum
01.08.2020
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 8/2020
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-020-00922-8

Weitere Artikel der Ausgabe 8/2020

Current Allergy and Asthma Reports 8/2020 Zur Ausgabe

Telemedicine and Technology (J Portnoy, Section Editor)

Wearable Technology and How This Can Be Implemented into Clinical Practice

Allergic Skin Diseases (L Fonacier and A Wollenberg, Section Editors)

Biologics for Allergic Dermatologic Diseases

Pediatric Allergy and Immunology (W Dolen, Section Editor)

Proton Pump Inhibitors in Children: the Good, the Bad, and the Ugly

Asthma (V Ortega, Section Editor)

Occupational Exposure to Metals and Solvents: Allergy and Airway Diseases

Pediatric Allergy and Immunology (W Dolen, Section Editor)

Chronic Urticaria in Children: an Update on Diagnosis and Treatment

Basic and Applied Science (I Lewkowich, Section Editor)

The Role of New IL-1 Family Members (IL-36 and IL-38) in Atopic Dermatitis, Allergic Asthma, and Allergic Rhinitis

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Tonsillektomie | Nachrichten

Intrakapsuläre Tonsillektomie gewinnt an Boden

15.04.2024 | Hörsturz | Nachrichten

Bilateraler Hörsturz hat eine schlechte Prognose

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“
weitere anzeigen

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen